Renal risk associated with sodium phosphate medication: safe in healthy individuals, potentially dangerous in others.

Michal Andel, Pavel Kraml, Iva Hoffmanová

Journal: Expert opinion on drug safety 2016;14(7):1097-110

PMID: 26084636

Abstract

INTRODUCTION

Sodium phosphate purgatives are used for bowel preparation before endoscopic or radiologic examination and occasionally for treatment of severe obstipation. Generally, they are well tolerated and effective; however, safety concerns exist regarding serious renal injury and electrolyte disturbances after administration of these drugs.

AREAS COVERED

The review presents complications associated with the use of agents containing sodium phosphate with regard to electrolyte disorders and renal impairment, namely acute phosphate nephropathy (APhN). This paper discusses the pathophysiology, histopathological findings, clinical symptoms, diagnosis and treatment of APhN. Additionally, it examines the epidemiology of adverse renal events and the safety of using sodium phosphate preparations prior to colonoscopy.

EXPERT OPINION

Because of safety concerns, sodium phosphate purgatives are not recommended for routine bowel cleansing. Despite some serious and even fatal adverse events associated with these drugs when used with at-risk patients, available data suggest that administration of sodium phosphate purgatives is relatively safe in nonrisk individuals(i.e., in adequately hydrated, otherwise healthy adults, younger than 55 years with evidence of normal renal function).

Address: Charles University in Prague, 2nd Department of Internal Medicine, Third Faculty of Medicine , Ruská 87, 100 00 Prague 10 , Czech Republic +420 723 705 493, +420 267 162 703 ; [email protected].

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.